Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma

por Kenney, Cara, Kunst, Tricia, Webb, Santhana, Christina, Devisser, Arrowood, Christy, Steinberg, Seth M., Mettu, Niharika B., Kim, Edward J., Rudloff, Udo
Publicado 2021

A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency

por Amarnani, Abhimanyu A., Poladian, Katlin R., Marciano, Beatriz E., Daub, Janine R., Williams, Sandra G., Livinski, Alicia A., Hsu, Amy P., Palmer, Cindy L., Kenney, Cara M., Avila, Daniele N., Holland, Steven M., Katz, James D.
Publicado 2020

Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy

por Taylor Ripley, R., Surman, Deborah R., Diggs, Laurence P., Trepel, Jane B., Lee, Min-Jung, Ryan, Jeremy, Davis, Jeremy L., Steinberg, Seth M., Hernandez, Jonathan M., Hoang, Choung, Kenney, Cara M., Bond, Colleen D., Kunst, Tricia F., Letai, Anthony, Schrump, David S.
Publicado 2018

Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies

por Zhang, Mary, Hong, Julie A., Kunst, Tricia F., Bond, Colleen D., Kenney, Cara M., Warga, Cheryl L., Yeray, Javier, Lee, Min-Jung, Yuno, Akira, Lee, Sunmin, Miettinen, Markku, Ripley, R. Taylor, Hoang, Chuong D., Gnjatic, Sacha, Trepel, Jane B., Schrump, David S.
Publicado 2021